Murat is a Clinical Neuropsychologist and NHMRC Principal Research Fellow. As well as being BrainPark's Founding Director, Murat is Leader of the Addiction and Mental Health Program within the Turner Institute for Brain and Mental Health is a Principal Investigator on MDMA and psilocybin clinical trials. His work combine's neuroscience with lifestyle and technology-based immersive interventions (such as physical exercise, mindfulness mediation, yoga, virtual reality, and cognitive training) to drive the creation of a new generation of lifestyle and technology-based tools and strategies that enable engaging and effective monitoring and enhancement of mental wellbeing, particularly for people with compulsive behaviours; from unhealthy habits through to addictions and obsessive compulsive disorder. Murat has been named in the 0.1% of the most Highly Cited (HiCi) researchers in the world on five occasions (2015, 17-20). Murat is an advisor to Enosis, and does not hold equity in the company or receive remuneration for this role.

Dr Margaret Ross (PsyD) is the Chief Principal Investigator and clinical lead for Australia’s first psilocybin-assisted psychotherapy study treating depression and anxiety in the terminally ill. Her study is a world first investigating psilocybin assisted therapy for all palliative conditions, and sees Dr Ross pioneering a new frontier in psychedelic medicine. Dr Ross combines oversight of this ground-breaking trial with palliative medicine clinical work in her role as Senior Clinical Psychologist and Researcher at St Vincent’s Hospital in Melbourne and also trains clinicians in emerging psychedelic assisted therapy drug trials. She regularly lectures medical students and specialist clinicians in psychosocial aspects of palliative medicine and cancer care. Margaret is an advisor to Enosis, and does not hold equity in the company or receive remuneration for this role.

Paul is Head of Clinical Psychedelic Research at Monash University, and Chief Principal Investigator on a program of psychedelic trials at Monash University. He has an Honours in Neuroscience and a PhD in Psychology from the University of Melbourne, and has Adjunct or Honorary appointments at St Vincent’s Hospital, Macquarie University, Deakin University, and the University of Melbourne. He is an Investigator on a number of Australia’s first few ethically-approved psychedelic trials, coordinates Australia’s first applied psychedelic therapist training programs, has obtained the first industry funding and partnership for psychedelics in Australia, is establishing Australia’s largest psychedelic trial, and leads Australia’s first clinical psychedelic lab. His work is focused on developing a rigorous program of research in psychedelic medicine that seeks to evaluate therapeutic effects, innovate on treatment design, mitigate known risks, explore potential drawbacks, and understand therapeutic mechanisms. Paul is an advisor to Enosis, and does not hold equity in the company or receive remuneration for this role.